The Financial Times has taken a majority stake in B2B biopharmaceutical website Endpoints News.

The FT said the acquisition marks a “significant milestone” in its expansion into the US and deepens its coverage of the biopharmaceutical sector. It also brings the subscription-based business a further 163,000 subscribers into the mix.

FT chief executive John Ridding said: “We’re thrilled to invest in Endpoints, a fast-growing business with a robust reputation for delivering quality news to audiences across the biopharma ecosystem.